These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 23991695)
1. RET fusion gene: translation to personalized lung cancer therapy. Kohno T; Tsuta K; Tsuchihara K; Nakaoku T; Yoh K; Goto K Cancer Sci; 2013 Nov; 104(11):1396-400. PubMed ID: 23991695 [TBL] [Abstract][Full Text] [Related]
2. Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations. Nishimura T; Nakamura H Adv Exp Med Biol; 2016; 926():115-137. PubMed ID: 27686809 [TBL] [Abstract][Full Text] [Related]
4. RET fusions in solid tumors. Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421 [TBL] [Abstract][Full Text] [Related]
5. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307 [TBL] [Abstract][Full Text] [Related]
6. ALK inhibitors in the treatment of advanced NSCLC. Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927 [TBL] [Abstract][Full Text] [Related]
7. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636 [TBL] [Abstract][Full Text] [Related]
8. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma. Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518 [TBL] [Abstract][Full Text] [Related]
9. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984 [TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866 [TBL] [Abstract][Full Text] [Related]
11. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells. Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490 [TBL] [Abstract][Full Text] [Related]
12. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208 [TBL] [Abstract][Full Text] [Related]
13. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Suzuki M; Makinoshima H; Matsumoto S; Suzuki A; Mimaki S; Matsushima K; Yoh K; Goto K; Suzuki Y; Ishii G; Ochiai A; Tsuta K; Shibata T; Kohno T; Esumi H; Tsuchihara K Cancer Sci; 2013 Jul; 104(7):896-903. PubMed ID: 23578175 [TBL] [Abstract][Full Text] [Related]
14. Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. Saito M; Shimada Y; Shiraishi K; Sakamoto H; Tsuta K; Totsuka H; Chiku S; Ichikawa H; Kato M; Watanabe S; Yoshida T; Yokota J; Kohno T Cancer Res; 2015 Jun; 75(11):2264-71. PubMed ID: 25855381 [TBL] [Abstract][Full Text] [Related]
15. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255 [TBL] [Abstract][Full Text] [Related]
16. The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma. Zhu YC; Wang WX; Zhang QX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y Clin Lung Cancer; 2019 Jan; 20(1):e73-e76. PubMed ID: 30366769 [No Abstract] [Full Text] [Related]
17. RET, ROS1 and ALK fusions in lung cancer. Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623 [TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864 [TBL] [Abstract][Full Text] [Related]
19. [Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer]. Zheng Y; Jiang W; Chen D; Li Y; Dai L; Huang L; Wang M Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):591-597. PubMed ID: 34120433 [TBL] [Abstract][Full Text] [Related]
20. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Ju YS; Lee WC; Shin JY; Lee S; Bleazard T; Won JK; Kim YT; Kim JI; Kang JH; Seo JS Genome Res; 2012 Mar; 22(3):436-45. PubMed ID: 22194472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]